PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 Visninger
• 07/08/23
0
0
Indlejre
administrator
Abonnenter
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
Vis mere
Facebook kommentarer
SORT BY-
Topkommentarer
-
Seneste kommentarer